These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16646082)

  • 1. Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells.
    Narayanan NK; Narayanan BA; Bosland M; Condon MS; Nargi D
    Int J Cancer; 2006 Oct; 119(7):1586-98. PubMed ID: 16646082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
    Narayanan NK; Narayanan BA; Reddy BS
    Int J Oncol; 2005 Mar; 26(3):785-92. PubMed ID: 15703837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
    Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV
    Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).
    Narayanan BA; Condon MS; Bosland MC; Narayanan NK; Reddy BS
    Clin Cancer Res; 2003 Aug; 9(9):3503-13. PubMed ID: 12960143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.
    Katkoori VR; Manne K; Vital-Reyes VS; Rodríguez-Burford C; Shanmugam C; Sthanam M; Manne U; Chatla C; Abdulkadir SA; Grizzle WE
    Biotech Histochem; 2013 Jan; 88(1):38-46. PubMed ID: 23167625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
    Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
    Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
    Narayanan BA; Narayanan NK; Pttman B; Reddy BS
    Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
    Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
    Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
    Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
    Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
    J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells.
    Song YC; Kim SH; Juhnn YS; Song YS
    Ann N Y Acad Sci; 2007 Jan; 1095():26-34. PubMed ID: 17404014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.
    Negi AK; Kansal S; Bhatnagar A; Agnihotri N
    Tumour Biol; 2013 Dec; 34(6):3753-64. PubMed ID: 24057882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.
    Kulp SK; Yang YT; Hung CC; Chen KF; Lai JP; Tseng PH; Fowble JW; Ward PJ; Chen CS
    Cancer Res; 2004 Feb; 64(4):1444-51. PubMed ID: 14973075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer.
    Kashiwagi E; Shiota M; Yokomizo A; Inokuchi J; Uchiumi T; Naito S
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):10-7. PubMed ID: 24518515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
    Park MA; Yacoub A; Rahmani M; Zhang G; Hart L; Hagan MP; Calderwood SK; Sherman MY; Koumenis C; Spiegel S; Chen CS; Graf M; Curiel DT; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2008 Apr; 73(4):1168-84. PubMed ID: 18182481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS.
    Piplani H; Vaish V; Sanyal SN
    Eur J Cancer Prev; 2012 Nov; 21(6):511-22. PubMed ID: 22441428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
    Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.